Parexel Biotech conducting Ph IIa neurodegenerative disease trial

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Zinkevych)
(Image: Getty/Zinkevych)

Related tags: Parexel Biotech, Clinical trial

AlzProtect is collaborating with Parexel Biotech to advance a Phase IIa clinical trial of its lead candidate, AZP2006, which is being developed for the treatment of a rare neurodegenerative disease.

Alzprotect is a biopharmaceutical company focused on developing drugs for the treatment of progressive supranuclear palsy (PSP) and Alzheimer's disease.

Parexel Biotech today announced that it has been selected to conduct the clinical Ph IIa development of AZP2006, Alzprotect’s flagship product.

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted AZP2006 orphan drug status in the indication of PSP.

AZP2006 was previously tested in two Phase I trials and demonstrated excellent tolerability, with no adverse effects, according to the company.

Parexel Biotech’s offering will include regulatory and strategic consulting, the ability to recruit patients and conduct trials, generation of real-world evidence (RWE) leveraging internal expertise and partnerships, such as with Datavant and SHYFT Analytics, among others.

The contract research organization (CRO) launched​ the dedicated biotech division earlier this year.

Related topics: Clinical Development, Phase I-IV

Related news

Show more

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

Syne Qua Non Clinical | 16-May-2018 | Business Advice

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars